This content is from: Corner Office Short Sellers Hurt by Gilead’s Kite Acquisition Kite Pharma has likely been a target for bearish bets because the cancer-fighting technology it uses — CART — is new to the market, says Wedbush biotechnology analyst David Nierengarten. By Alicia McElhaney August 28, 2017
This content is from: Portfolio The Morning Brief: UC Employee Union Attacks Hedge Funds By Stephen Taub March 02, 2016
This content is from: Portfolio Investing in a Cure for Cancer The recently launched Loncar Cancer Immunotherapy ETF provides investors with a vehicle to bet on promising new immunotherapy treatments for cancer. By Kaitlin Ugolik June 07, 2016
This content is from: Premium The Hottest Sector Has Attracted the Most Short Interest Longs and shorts are having a tug-o-war over red-hot biotechnology stocks. By Stephen Taub September 11, 2017
This content is from: Corner Office Bayer’s Monsanto Deal Highlights Genetic Engineering Opportunities German pharmaceuticals giant Bayer’s $66 billion acquisition of Monsanto is about more than just seeds. By Kaitlin Ugolik September 14, 2016
This content is from: Portfolio The Morning Brief: Companies Not Prepared for Activist Attacks By Stephen Taub October 07, 2015
